Skip to content

Tools

Compare any two compounds

We write up the pairs people actually confuse, and there are only so many of those — 82 compounds make more than three thousand possible pairs. This puts any two of them on the same rows, read straight from both profiles. Where we have written the comparison properly, it says so and links you there.

We have written this one up

Semaglutide vs tirzepatide — with sourcing, mechanism and the things a table cannot hold. The rows below are the short version.

Semaglutide compared with Tirzepatide
PropertySemaglutideTirzepatide
EvidenceApprovedApproved
Categoryweight lossweight loss
Regulatory statusApproved by the FDA as a prescription medicine for type 2 diabetes and for chronic weight management.Approved by the FDA as a prescription medicine for type 2 diabetes and for chronic weight management.
Half-lifeAbout 7 daysAbout 5 days
Routesubcutaneoussubcutaneous
Frequency reportedOnce weekly; Once weekly, raised in steps every four weeksOnce weekly; Once weekly, raised by 2.5 mg every four weeks
Dose reported250 mcg2.5 mg
Sold in vials of2 mg, 3 mg, 5 mg, 10 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 60 mg
Monitoring markers3 recorded3 recorded
Citations on the profile11

Every value is read from the two profiles, and “not recorded” means exactly that — we have not found a source we trust for it, not that the answer is zero. Neither column is a recommendation, and nothing here says which compound suits anyone. Read Semaglutide and Tirzepatide in full before drawing conclusions from a table.

Bioalmanac does not recommend compounds and takes no vendor placement. A comparison describes differences; it does not identify a better option for you.